BPaL is a six-month three-drug alloral regimen used to treat people with highly drug-resistant forms of tuberculosis. It consists of the TB Alliance developed the antibiotic pretomanid, along with two other antibiotics: bedaquiline and linezolid. While the BPaL regimen was approved by the drug regulator in India last year, the results of the latest TB Alliance trial show that the high efficacy of the BPaL regimen can be maintained with a lower dose of linezolid, which is associated with challenging side effects, including peripheral neuropathy. This is expected to boost the use of the drug. “TUBERCULOSIS alliance is encouraged by these results, which support the use of reduced-dose linezolid in the six-month, three-drug, fully oral BPaL regimen, ”says Alliance President and CEO Mel Spigelman. Although many patients discontinue treatment due to the duration of current treatment, older treatment regimens require more than 18 months of five or more drugs with low treatment success rates. India accounts for more than 1 in 4 of all active TB disease cases, including nearly 1.20 thousand cases of drug-resistant forms of TB. “Innovative approaches to turn the tide of TB are urgently needed and essential to achieving national and global TB elimination targets. Brief, simple, safe and effective therapies should be the cornerstone of any tuberculosis control effort. By reducing the cost and time of treatment required for highly drug-resistant forms of tuberculosis, tuberculosis programs can free themselves to dedicate scarce resources to treating forms of the disease and other serious challenges such as controlling Covid-19 ”, says Spigelman. A national tuberculosis control program in India recorded a 25% drop in the detection of new patients during the first half of 2021 compared to the corresponding period in 2019. who estimates that these Covid-19-related disruptions in access to TB care could cause an additional half a million deaths, missing a decade’s progress.